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Abstract
Background: The magnitude and rapidity of the tumor response to androgen deprivation is known to predict the
durability of the therapy. We have investigated the predictive value of categorizing patients by the half-life of PSA
under neoadjuvant androgen deprivation therapy in patients with biochemical recurrence after radical prostatectomy.
Methods: Medical records of 317 patients who received neoadjuvant androgen deprivation therapy before radical
prostatectomy and developed biochemical recurrence were analyzed. The patients were categorized into five groups
according to PSA half-life. Risk of developing castration resistance was evaluated by Kaplan-Meier analysis and by Cox
proportional risk regression analysis.
Results: The median follow-up duration was 50.1 months (IQR 31.8–68.7) and median PSA half-life was 22.1 days
(IQR 12.7–38.4). Comparison of survival curves revealed that patients in the intermediate response group showed
significantly lower 5-year castration-resistant prostate cancer rate (37.5%) compared to non-response and ultra-rapid
response groups (63.6%, p = 0.007; 56.1%, p = 0.031; respectively). In the multivariate regression model, intermediate
response compared to non-response was associated with significantly reduced risk of castration resistance development
(hazard ratio 0.397, 95% confidence interval 0.191–0.823, p = 0.013) and overall mortality (hazard ratio 0.138, 95%
confidence interval 0.033–0.584, p = 0.007). When subcategorized by Gleason score, Kaplan-Meier curve revealed
that, in the high Gleason score stratum, 5-year castration-resistant prostate cancer rate for intermediate response
group (44.0%) was exceptionally lower than that in non-response group (66.7%, p = 0.047), while castration resistance
increased in other groups.
Conclusion: Short PSA half-life as well as no response after androgen deprivation is associated with increased risk of
treatment failure compared to intermediate PSA half-life.
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Background
Androgen deprivation therapy (ADT) has been the pre-
ferred therapy for prostate cancer patients with bio-
chemical recurrence (BCR) after definitive local therapy.
Despite the initial tumor suppressing effect, the majority
of patients develop resistance to medical castration
within 2–3 years, rendering the ADT ineffective [1–3].
Modification of the androgen receptor is believed to be
the most important cause underlying castration-resistant
prostate cancer (CRPC) development, which enables
androgen-independent activation of the androgen recep-
tor or alters its sensitivity [1]. Nevertheless, it is known
that the androgen axis continues to play an important
role in the function and growth of CRPC [1, 4].
Regarding the risk of developing CRPC, there has been
a notion that the magnitude [5] and rapidity [6] of the
tumor response to ADT can reliably predict the durabil-
ity of the therapy. Some prior studies suggest that a
shorter time to nadir or prostate-specific antigen half-
life (PSAT½) during ADT is associated with longer
CRPC-free survival and cancer-specific survival [7, 8].
However, there have been some recent studies with
contradictory results, reporting shorter remission period
and poorer survival in rapid response groups undergone
ADT [9, 10]. Because tumor response to ADT may vary
[11] and some prostate cancer cells are known to pro-
duce little, if any, prostate-specific antigen (PSA) [12],
the resultant PSA kinetics can be heterogeneous in na-
ture [3].
Under the assumptions that the risk of developing
CRPC can be measured by analyzing the PSA response
to hormone therapy and that castration resistance is het-
erogeneous among the individual tumor cells within a
patient, we investigated the value of the PSAT½ during
neoadjuvant ADT as a predictive factor for CRPC in rad-
ical prostatectomy patients who developed BCR.
Methods
Patient population
With approval from the Severance Hospital Institutional
Review Board (protocol number 4–2016-0506), the clin-
ical information and follow-up data of patients who
underwent bilateral nerve-sparing radical prostatectomy
in a single center by a single operator (Y.D.C.) between
2002 and 2014 were collected. Informed consent from
the participants was waived by the institutional review
board. Patients who received neoadjuvant ADT and de-
veloped BCR (n = 348) were selected. Patients with miss-
ing data (n = 18) or those who received adjuvant
radiotherapy prior to or on the day of BCR diagnosis (n
= 13) were excluded from the cohort, leaving 317 pa-
tients for analysis. No patients were given cytotoxic
chemotherapy before the confirmation of CRPC.
Neoadjuvant therapy and preoperative parameters
Neoadjuvant hormone therapy in the study cohort con-
sisted of bicalutamide monotherapy (50 mg bid), admin-
istered based on treating physician’s decision. Regression
due to neoadjuvant therapy was noted on most of the
specimens, and in 7 (2%) patients the regression was so
extensive that there were no tumor cells detectable des-
pite the positive results on preoperative biopsy. Median
duration of neoadjuvant ADT was 53 (interquartile
range [IQR] 35–106) days. Initial PSA was measured at
the time of screening immediately before the transrectal
ultrasound-guided prostate biopsy. Preoperative serum
PSA levels were sampled the day before the operation.
PSAT½ was calculated by the following formula [13]:
PSAT1=2 ¼ dt ln2 lnPSA0−lnPSAtð Þ
where dt = time interval between measurement (days),
PSA0 = initial PSA, and PSAt = preoperative PSA at time
t after the initial measurement. With use of the ultrasen-
sitive PSA essay, an undetectable level of PSA was con-
sidered equivalent to 0.01 ng/mL.
Postoperative follow-up
A patient was considered to have BCR when a postoper-
ative PSA level 0.2 ng/mL above the nadir was detected
after reaching a nadir PSA value of 0.1 ng/mL. Adjuvant
ADT was delivered as a luteinizing hormone releasing
hormone (LHRH) agonist alone, a combination of LHRH
agonist with antiandrogen, or antiandrogen monother-
apy, given at the discretion of the treating urologist
(Y.D.C.).
CRPC was defined as three consecutive elevated PSA
levels after BCR, or detection of metastasis on radio-
logical images. In the absence of three increased PSA
measurements, salvage radiotherapy on equivocal find-
ings in radiological images was also counted as a CRPC
event. Time to CRPC was determined by subtracting the
date of BCR from the date of CRPC event.
Statistical analysis
The patient cohort was classified into five groups by
PSAT½ in 15-day intervals (non-responders [below 0:
PSA increased or unchanged], ultra-rapid responders
[0~15], rapid responders [15~30], intermediate re-
sponders [30~45], and slow responders [over 45]). Com-
parison of parameters between groups was performed
using Fisher’s exact test, Mann–Whitney U test, and
Kruskal-Wallis test. Survival analysis was performed by
plotting Kaplan-Meier curves with a pairwise log-rank
test and by constructing multivariate Cox proportional
hazard regression models. All statistical analyses were
performed using the Statistical Package for Social Sci-
ences v.22.0 for Windows (SPSS; Chicago, Illinois). A p-
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value <0.05 on two-tailed test was considered statistically
significant in the current study.
Results
Baseline characteristics
Baseline cohort characteristics are listed in Table 1. Me-
dian follow-up duration was 50.1 months (IQR 31.8–
68.7). Median initial PSA was 23.2 ng/mL (IQR 11.7–48.9)
and median preoperative PSA was 3.39 ng/mL (IQR 0.87–
7.66). Median PSAT½ was 22.1 days (IQR 12.7–38.4). The
number of patients assigned to each PSAT½ group, in
order of increasing PSAT1/2, was 22 (6.9%), 82 (25.9%),
104 (32.8%), 40 (12.6%), and 69 (21.8%). There were 64
(20.2%) pathologic T2, 236 (74.4%) T3, and 17 (5.4%) T4
patients in the cohort, with no significant difference
among groups (p = 0.623). There were 14 (4.4%) patients
at or below Gleason score 6, 106 (33.4%) patients at Glea-
son score 7, and 197 (62.1%) patients at or above Gleason
score 8. There was no significant difference between
groups in terms of Gleason score (p = 0.077). There was
no significant difference in duration of exposure to antian-
drogen between groups, except for the slow response
group, which had a median exposure of 70 (IQR 36–314)
days compared to 35 (IQR 22–46) days in the non-
responding group (p = 0.004).
Kaplan-Meier analysis for CRPC-free survival categorized
by PSAT½ group
Overall, 147 patients (46.4%) with BCR developed CRPC.
Pairwise analysis of Kaplan-Meier curve (Fig. 1a) revealed
that in comparison to non-response group, 5-year CRPC
rate of the intermediate response group was significantly
lower (37.5% vs. 63.6%, respectively; p = 0.007). Rapid and
slow response groups also showed significantly lower rate
of CRPC than non-response group (41.3%, 40.6%; p =
0.010, 0.041, respectively). CRPC rate in ultra-rapid
responding group was similar (56.1%; p = 0.248) to non-
responding group, and the difference with intermediate
response group was also significant (p = 0.031). Differ-
ences between rapid or slow response groups and inter-
mediate response group were not significant (p = 0.478,
0.376, respectively).
Analysis of overall mortality yielded similar results
(Fig. 1b), with rapid and intermediate response groups
showing improved 5-year mortality rate compared to non-
responding group (7.7%, 2.5% vs. 27.3%; p = 0.016, 0.008,
respectively). Although CRPC rate was lower in the slow
response group, mortality rate difference with non-
responding group was revealed to be not significant (5.8%;
p = 0.077). Except for non-responding group, there was no
significant difference in mortality between intermediate
response group and ultra-rapid, rapid, and slow response
groups (p = 0.247, 0.338, 0.419, respectively).
Multivariate Cox proportional hazards regression analysis
To control the effects from other known prognostic fac-
tors, multivariate models were constructed (Table 2). On
univariate analysis, rapid, intermediate, slow response
groups (p = 0.011, 0.007, 0.032, respectively), Gleason
score > 7 (p = 0.013), and pathologic T4 stage (p = 0.034)
Table 1 Baseline characteristics
PSA half-life categories
Non-responder
(n = 22)
Ultra-rapid responder
(n = 82)
Rapid responder
(n = 104)
Intermediate responder
(n = 40)
Slow responder
(n = 69)
Median (IQR)/n (%) Median (IQR)/n (%) Median (IQR)/n (%) Median (IQR)/n (%) Median (IQR)/n (%)
Initial PSA (ng/mL) 9.6(7.7~15.2) 33.0(16.5~61.6) 23.6(12.3~47.5) 22.8(12.1~50.5) 16.0(10.2~40.9)
Immediate preoperative PSA
(ng/mL)
14.3(9.6~21.1) 0.9(0.4~2.6) 2.5(0.8~6.3) 4.6(2.1~9.2) 5.4(3.7~10.4)
ADT exposure duration (days) 35.0(22.0~46.0) 51.5(37.0~78.0) 63.5(34.0~112.5) 51.5(36.0~149.5) 70.0(36.0~314.0)
PSAT½ −196.8(−912.9~ − 47.2) 11.3(9.9~12.9) 21.6(18.3~24.0) 33.4(32.4~38.6) 94.2(54.9~148.4)
Pathologic T stage II 3(13.6) 13(15.9) 21(20.2) 11(27.5) 16(23.2)
III 17(77.3) 64(78.0) 77(74.0) 29(72.5) 49(71.0)
IV 2(9.1) 5(6.1) 6(5.8) 0(0) 4(5.8)
Pathologic Gleason score ≤6 2(9.1) 2(2.4) 3(2.9) 3(7.5) 4(5.8)
7 5(22.7) 19(23.2) 43(41.3) 12(30.0) 27(39.1)
≥8 15(68.2) 61(74.4) 58(58.7) 25(62.5) 38(55.1)
CRPC No 7(31.8) 36(43.9) 61(58.7) 25(62.5) 41(59.4)
Yes 15(68.2) 46(56.1) 43(41.3) 15(37.5) 28(40.6)
Time to CRPC (months) 13.2(6.1~21.9) 16.1(8.9~27.8) 18.8(10.0~41.2) 32.8(12.6~50.0) 18.0(6.9~43.5)
PSA prostate-specific antigen, IQR interquartile range, ADT androgen deprivation therapy, CRPC castration-resistant prostate cancer, PSAT½ prostate-specific
antigen half-life
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showed significant association with CRPC risk. Age
(p = 0.204), initial PSA ≥20 ng/mL (p = 0.170) and ex-
posure duration (p = 0.169) showed no significant as-
sociation with CRPC. Multivariate Cox regression was
performed using variables found significant in the univari-
ate analysis. In the multivariate model, intermediate
response to neoadjuvant treatment significantly predicted
reduced risk for CRPC (hazard ratio [HR] 0.397, 95% con-
fidence interval [CI] 0.191–0.823, p = 0.013) compared to
non-responding group. Rapid response was also asso-
ciated with decreased risk (HR 0.499, 95% CI 0.271–
0.920, p = 0.026), but slow response did not show
(a) (b)
Fig. 1 Kaplan-Meier curve for a CRPC-free survival and b OS categorized by PSAT½
Table 2 Multivariate Cox regression model for CRPC and overall mortality risk with PSAT½ groups as parameters
CRPC Overall mortality
Univariate Multivariate Univariate Multivariate
p-value HR 95% CI p-value p-value HR 95% CI p-value
Age Continuous 0.204 0.995 0.970–1.022 0.734 0.243 1.046 0.990–1.105 0.107
Initial PSA ≥20 ng/mL 0.170 0.154
Gleason score >7 0.013* 1.472 1.018–2.128 0.040* 0.006* 3.127 1.361–7.187 0.007*
PSAT½ (days) Non-responder (below 0) (reference) (reference)
Ultra-rapid responder (0~15) 0.279 0.702 0.390–1.263 0.238 0.189 0.443 0.168–1.164 0.099
Rapid responder (15~30) 0.011* 0.499 0.271–0.920 0.026* 0.018* 0.295 0.109–0.797 0.016*
Intermediate responder (30~45) 0.007* 0.397 0.191–0.823 0.013* 0.011* 0.138 0.033–0.584 0.007*
Slow responder (over 45) 0.032* 0.553 0.289–1.057 0.070 0.094 0.501 0.183–1.368 0.177
Pathologic T stage Below T2 (reference) (reference)
T3 0.915 0.966 0.634–1.471 0.870 0.013* 4.987 1.187–20.946 0.028*
T4 0.034* 1.831 0.921–3.642 0.085 0.009* 9.521 1.799–50.402 0.008*
ADT exposure duration (days) Continuous 0.169 0.386
HR hazard ratio, CI confidence interval, PSA prostate-specific antigen, ADT androgen deprivation therapy, PSAT½ prostate-specific antigen half-life
*statistically significant at p < 0.05
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significance (p = 0.094) when other factors were considered.
Ultra-rapid response did not affect the risk significantly in
the multivariate model (p = 0.238) as well as in the univari-
ate analysis. Among factors other than PSAT½, Gleason
score > 7 (HR 1.472, 95% CI 1.018–2.128, p = 0.040) was
also significantly associated with increased CRPC risk.
Protective effect of intermediate response could be also
observed in the multivariate model for overall survival. In
the univariate analysis, Gleason score > 7, rapid response,
intermediate response, T3 and T4 stage showed association
with overall mortality (p = 0.006, 0.018, 0.011, 0.013, and
0.009, respectively). Age (p = 0.243) and the duration of ex-
posure to ADT (p = 0.386) was not associated with overall
survival as well. In the multivariate model, intermediate re-
sponse was associated with significanly decreased mortality
risk (HR 0.138, 95% CI 0.033–0.584, p = 0.007), followed by
rapid response (HR 0.295, 95% CI 0.109–0.797, p = 0.016).
Ultra-rapid response and slow response did not show asso-
ciation with overall mortality (p = 0.099, 0.177). In addition
to Gleason score (HR 3.127, 95% CI 1.361–7.187, p =
0.007), high T stage increased the mortality risk (T3: HR
4.987, 95% CI 1.187–20.946, p = 0.028; T4: HR 9.521, 95%
CI 1.799–50.402, p = 0.008) in our model.
Kaplan-Meier analysis further subcategorized by Gleason
score
Patients were further categorized into low to interme-
diate Gleason score (≤7) and high Gleason score (>7)
strata to analyze the influence of poor differentiation on
CRPC rate in the PSAT½ groups (Fig. 2). When stratified
according to Gleason score group, 5-year CRPC rate for
non-responding patients was exceptionally higher
(71.4%) compared to patients in rapid and slow response
groups (32.6%, p = 0.020; 29.0%, p = 0.027; respectively)
for the low to intermediate Gleason score stratum. Al-
though CRPC rate was lower in intermediate and ultra-
rapid response groups, the difference was not significant
(26.7%, p = 0.076; 47.6%, p = 0.405, respectively). In the
high Gleason score stratum, there were no statistically
significant differences between the non-response group
and other groups (p = 0.437, 0.174, and 0.468, for ultra-
rapid, rapid, and slow response group, respectively). The
only exception to this was intermediate response group,
in which CRPC rate was significantly lower than in non-
response group (44.0% vs. 66.7%, p = 0.047).
Discussion
In the current study, we have attempted to identify pa-
tients at risk of developing CRPC by quantifying the re-
sponse to ADT before the operation. By classifying
according to preoperative PSAT½, we could identify pa-
tients at lower risk of developing CRPC from patients at
high risk. Of note, our results indicate that group of pa-
tients with longer PSAT½ (30 to 45 days) can actually
have lower CRPC rate, and that shorter PSAT½ is not
necessarily associated with low risk of developing CRPC.
(a) (b)
Fig. 2 Kaplan-Meier curve of PSA half-life groups for CRPC stratified by Gleason score. a Gleason ≤7 stratum b Gleason >7 stratum
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By avoiding the need to wait for PSA to achieve nadir,
PSAT½ serves as a handy proxy for the response to ADT
in the neoadjuvant setting. However, evidences so far are
conflicting regarding whether the longer PSAT½ should
be taken as a synonym for a longer remission period. In
their study on PSAT½ during maximal androgen block-
ade in CRPC patients later treated with docetaxel, Lin et
al. [7] concluded that PSAT½ > 0.5 months shortens
CRPC-free survival and cancer-specific survival (HR
3.41, p = 0.026). On the contrary, Kim et al. [10] sug-
gested that PSAT½ ≥ 0.5 months after ADT is a condi-
tion associated with increased survival after docetaxel
chemotherapy. Such contradictory results may in part
come from the fact that PSAT½ over 0.5 months repre-
sents a different subset of patients in each study, as the
cohort from the former study consisted of patients with
median PSAT½ of 0.5 (IQR 0.1–34.2) months, while the
median was 0.9 (IQR 0.5–2.0) months in the latter. Add-
itionally, in the study by Kim et al. where mean values
with standard deviations were also available, the mean
was 3.5 ± 9.2 months, implying that the range included
negative values. Because negative half-life corresponds to
PSA doubling time [13], which means a failure to
achieve nadir PSA and a resistance to ADT, it would be
more appropriate to categorize the patients with nega-
tive values as a separate group.
In the current study, patients with PSAT½ shorter than
15 days presented with increased CRPC risk comparable
to that of non-response group (Fig. 1a). A number of other
studies also point out that a rapid response to ADT, mea-
sured by short PSAT½ [10, 14] or time to nadir [15, 16], as
an independent predictor of poor survival in patients with
CRPC. The mechanism underlying the increase in CRPC
risk for patients with steep PSA decline remains largely
unknown, but postulated theories suggest that it is a result
of the transcriptional effect of ADT on PSA production
rather than prostate cancer cell death [16]; rapid removal
of hormone-sensitive prostate cancer cells inducing an ad-
equate environment for the growth of hormone-resistant
prostate cancer cells [9]; or high probability of these sub-
sets of patients containing cancers with low PSA produc-
tion, such as cells with neuroendocrine differentiation [10]
or cancer stem cells [17]. Westin et al. [18] demonstrated
that the apoptotic activities are not uniformly increased in
tumors responding to the androgen ablation with cellular
atrophy and decreased cell proliferation rate. Considering
that a decline in cell proliferation rate rapidly peaks within
7 days after castration but tumor apoptosis is found in
only 30% of the patients [19], it is more likely that prema-
ture PSA decrease observed in our study was a result of
halted proliferation rather than cell death. Acquisition of
castration resistance in these dormant cells can result in
regrowth despite the initial quick response to the andro-
gen deprivation.
As expected, non-responders to ADT with negative
PSAT½ showed increased CRPC risk as demonstrated by
the higher CRPC rate for the non-responding group
(63.6%) than the rapid response and slow response
groups (Fig. 1a). These findings are in good agreement
with previous literatures where an increase in PSA des-
pite the initiation of ADT was associated with generally
worse outcome. For instance, Matzkin et al. [5] showed
that the median progression-free interval, for the pa-
tients whose lowest PSA level was more than 50 ng/mL,
was significantly shorter than those who achieved nadir
(6 vs. 12 months, p < 0.0001).
In our multivariate regression model, the Gleason
score was the only parameter that was significantly asso-
ciated with increased risk of CRPC (HR 1.472, 95% CI
1.018–2.128, p = 0.040) other than PSAT½ (Table 2). An
increase in Gleason score is known to be strongly associ-
ated with higher CRPC risk. It is shown in the study by
Benaim et al. [20], that each unit of increase in Gleason
score increases the risk of progression into CRPC by
nearly 70% (HR 1.68, 95% CI 1.3–2.1, p < 0.0001). In the
low to intermediate Gleason score (≤7) patients, CRPC
rate was significantly lower in the rapid and slow re-
sponse groups when compared against the non-
responding group, while the gap was less explicit in the
high Gleason score (>7) patients, as can be seen in Fig. 2.
This increase of CRPC risk in poorly differentiated can-
cers is similar to the finding previously documented in
the study by Benaim et al. [20] in which low and inter-
mediate Gleason score patients experienced significantly
longer remissions compared to Gleason score 8 to 10
patients (52.1 vs 25.2 months, p = 0.0006). A notable ex-
ception to this was the intermediate response group,
which also showed significant association with markedly
decreased risk of CRPC in the multivariate model (HR
0.397, 95% CI 0.191–0.823, p = 0.013). In the high Glea-
son score (>7) stratum, 5-year CRPC rate (44.0%)
remained lowest for the intermediate responders, espe-
cially compared to the non-response group (60.0%, p =
0.047). It remains to be investigated in the future studies
why the group with a PSAT½ of 30 to 45 days main-
tained relatively longer remission while CRPC rate in
other groups uniformly increased to a level comparable
to non-responders.
A possible explanation can be that this is because pa-
tients in the current study were exposed to neoadjuvant
ADT before the normal prostate tissue was completely
removed by surgery. Non-malignant human prostate tis-
sue is reported to respond to ADT with apoptosis peak-
ing 3–4 days after castration but returning to normal
levels in approximately 2 weeks [21]. Ohlson et al. [19]
proposed that this effect was due to the presence of
remaining epithelium and basal cells. Considering that
malignant cells show pronounced (7-fold) apoptotic
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activity starting from day 3–4 of castration regardless
of Gleason score [19], latent proliferative activity could
be seen as a reflection of a higher proportion of be-
nign prostate cells being responsible for PSA secre-
tion, thus slowing the decline in serum PSA level
weeks after ADT.
The current study has some limitation to note. While
the majority of patients (74.8%) received adjuvant ADT
consisting of 3-month interval LHRH agonist (Goserelin,
Leuprolide and Triptorelin), a subset of patients went
under combined androgen blockade with Bicalutamide
(19.9%), or even Bicalutamide monotherapy (5.4%). Het-
erogeneous use of regimens may have interfered with
maintained suppression of androgen receptor, and thus
resulted in variations for PSA output. Although all pa-
tients went under routine biopsy process, its impact on
PSA level cannot be determined in this study. As it is ex-
pected to cause certain level of prostatitis, raising serum
PSA level, future study should consider incorporating
this factor in the model. Since there is no data available
regarding the serum testosterone levels of the cohort in
the current study, we could not pinpoint the mechanism
responsible for the observed risk increase in individual
groups. Proper evaluation is necessary for the association
between PSAT½ and the androgen activity to determine
which mechanism is impaired specifically in non-
responders and ultra-rapid responders.
Conclusion
Patients with PSAT½ of 30 to 45 days after neoadjuvant
therapy exhibited the lowest tendency to develop CRPC
compared to patients with no response or ultra-rapid re-
sponse who suffered high rate of adjuvant androgen
deprivation therapy failure. A 1- to 3-month neoadjuvant
ADT trial seems to be an effective way to identify pa-
tients who wound respond better to adjuvant ADT later,
and prevent unnecessary long term ADT for patients
who would not respond well to androgen deprivation.
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